Oncogene
This journal aims to make substantial advances in our knowledge of processes that contribute to cancer by publishing outstanding research.
MYBL2 promotes proliferation and metastasis of bladder cancer through transactivation of CDCA3
Our research reveals that MYBL2, a gene-regulating protein, is elevated in bladder cancer (BLCA) and linked to worse patient outcomes. It boosts BLCA growth and spread by activating the CDCA3 gene, working with FOXM1 to enhance cancer traits. This identifies MYBL2 as a key promoter of BLCA.
A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype
This study is the first report identifying a pathogenic EGFR germline mutation in prostate cancer, suggesting venues for germline screening, non-invasive diagnosis and monitoring in clinical practice.
Loss of DOCK2 potentiates Inflammatory Bowel Disease–associated colorectal cancer via immune dysfunction and IFNγ induction of IDO1 expression
In this paper we identify Dock2 as an immune regulator in IBD-CRC, with potential therapeutic opportunity in this area of unmet clinical need.
AF1q is a universal marker of neuroblastoma that sustains N-Myc expression and drives tumorigenesis
AF1Q is an oncogene with roles in leukemia and solid tumor progression. Despite its expression in neural tissues, no role for AF1Q in tumors of neural origin has been reported. We found AF1Q is a universal marker of neuroblastoma that is essential for neuroblastoma cell survival and tumorigenicity.
TRAIP suppresses bladder cancer progression by catalyzing K48-linked polyubiquitination of MYC
This study identified the significant role of TRAIP in inhibiting BLCA progression, and revealed that TRAIP expression is significantly downregulated in BLCA and is strongly associated with poor prognosis.